Full Breakdown
FDA's Shift in Drug Approval Standards: A Response to Global Competition
2/19/2026, 8:22:34 PM
U.S. Drug Development Under Pressure
Food and Drug Administration (FDA) Commissioner Dr. Marty Makary has raised concerns that the United States is losing its competitive edge to China in early-stage drug development. In a recent interview, Makary identified three significant bottlenecks—hospital contracting, ethical reviews, and the approval process for Investigational New Drug (IND) applications—that hinder the U.S. from keeping pace with faster-moving countries. He described the current situation as a "mess," emphasizing the need for reforms to streamline the initiation of clinical trials for new treatments.
Changes to Approval Standards
In a move aimed at accelerating drug availability, the FDA announced plans to eliminate its long-standing requirement for two rigorous studies to approve new drugs. Instead, the agency will adopt a "default position" of requiring only one study for new drugs and other novel health products. This decision, articulated by Makary and Dr. Vinay Prasad in a New England Journal of Medicine article, reflects a broader initiative to reduce bureaucratic hurdles and enhance the speed of drug approvals.
The FDA's historical reliance on two studies dates back to the early 1960s, when Congress mandated that the agency review data from "adequate and well-controlled investigations." However, advancements in drug research have prompted a reevaluation of this standard. Dr. Janet Woodcock, the former director of the FDA's drug center, noted that the new policy primarily impacts drugs for common diseases, which have not previously qualified for reduced testing standards.
Implications of the New Policy
The FDA's shift is expected to lead to a surge in drug development, particularly for common diseases. Over the past five years, approximately 60% of first-of-a-kind drugs have been approved based on a single study, especially for rare or fatal diseases. This trend aligns with legislative changes encouraging more flexible regulatory approaches for serious conditions. However, the FDA's recent actions regarding vaccines and gene therapies have raised questions about the consistency of its new stance. For instance, the agency recently rejected Moderna's application for a new mRNA flu shot due to insufficient clinical trial data, only to later agree to review it after the company committed to conducting additional studies.
Criticism and Concerns
Despite the potential benefits of the new policy, some experts caution that the FDA's approach must be carefully implemented. Woodcock emphasized that the drug industry will need to observe how the FDA's flexibility translates into practice. Critics have expressed concerns that the accelerated approval process could compromise the thoroughness of drug evaluations, particularly for treatments that may have significant safety implications.
What's Next for the FDA?
As the FDA moves forward with these reforms, the agency's leadership will need to balance the urgency of drug development with the necessity of ensuring patient safety and efficacy. The upcoming months will be critical in determining how these changes affect the landscape of drug approvals in the United States and its competitive standing in the global market.
